# Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

> **NCT02115659** · PHASE3 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD)

## Interventions

- **DRUG:** Triptolide-Containing Formulation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02115659
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115659, "Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)". Retrieved via AI Analytics 2026-06-20 from https://api.ai-analytics.org/clinical/NCT02115659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*